Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig plus chemotherapy versus nivolumab plus chemotherapy in previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
CTR20260794Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pumitamig in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Objective response rate, Progression-free survival and 1 more. Started Mar 2026; status: active.
02
Drugs
pumitamig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on CTR20260794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260794.